Home » Newsletters » BioWorld Science

BioWorld Science

May 27, 2002

View Archived Issues

Cymbalta relieves emotional and physical symptoms of depression without weight gain

Biomira updates progress of Theratope and BLP25

PSMA Development selects prostate cancer candidate

Euroscreen licenses CCR5 to Pfizer

Finnish approval for Metvix PDT

Novel factor VIIa inhibitors identified at Aventis

Janssen patents mGluR1 antagonists with analgesic activity

Selective N-type calcium channel blockers prepared at Ajinomoto

15-LO inducers and their use in inflammatory and autoimmune disorders

Androgen receptor modulators and their use described in Kaken patent

BMS describes novel series for immune and inflammatory disorders

Potent and selective PDE5 inhibitors claimed by Lilly Icos

New drug targeting SAP shows promise for Alzheimer's disease

Safety and preliminary evidence of efficacy reported for phenoxodiol in Australian study

Inhibitor of PKCbeta displays good safety in phase I study

MMP inhibitor evaluated for safety and pharmacokinetics in patients with advanced cancer

Nymox prepares IND for NX-1207

Zelapar NDA in Parkinson's disease accepted for filing

Camptothecin glycoconjugate well tolerated in early clinical trial in cancer patients

New strengths of Adderall XR approved for ADHD

MitoExtra NDA amendment accepted for filing

Copaxone prefilled syringes launched in Canada

Acceptable toxicity, disease stabilization in patients treated with BMS-310705

New indication and low dose strength of Vivelle-Dot approved

Pharmexa prepares to file IND for AutoVac HER-2 Protein pharmaccine for breast cancer

Discovery of potent IMPDH inhibitor with immunosuppressive and antiarthritic activity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 20, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 20, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...